Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 1,795 shares, a decrease of 31.6% from the June 30th total of 2,625 shares. Based on an average trading volume of 4,660 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the shares of the company are short sold.
Bavarian Nordic Stock Performance
BVNRY opened at $9.05 on Friday. Bavarian Nordic has a one year low of $8.67 and a one year high of $13.00. The stock has a market capitalization of $2.15 billion, a P/E ratio of 11.91 and a beta of 1.20. The business’s 50-day simple moving average is $9.35 and its 200-day simple moving average is $9.78.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $165.70 million during the quarter. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.
See Also
- Five stocks we like better than Bavarian Nordic
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
